A superiority designed study of Uygur medicine Luo-Ou-Ke Zu-Pa and Chinese medicine Xiao-Qing-Long-Tang Decoction in the treatment of cold asthma

Huashan Hospital Affiliated to Fudan University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Aged 18-75 years old at the time of enrollment;
•2. Patients with bronchial asthma diagnosed by modern medicine, regular inhaled hormone therapy or other conventional treatment 3 months later, patients with bronchial asthma ACT score <20 points;
•3. Patients with abnormal mucus type identified by Uighur medicine;
•4. Patients without upper and lower respiratory tract infections and not taking oral and intravenous glucocorticoid therapy within 2 weeks;
•5. Subjects voluntarily participated in the study and signed Informed consent.

•1. Patients in acute attack stage, who need oral and intravenous glucocorticoid therapy;
•2. Patients with abnormal blood type, abnormal savda type, and abnormal biliary type identified by Uygur medicine;
•3. Combined Patients with COPD, pulmonary fibrosis, and a history of lung resection;
•4. Pregnant or planning to become pregnant or breastfeeding women;
•5. Patients with malignant tumors and hematological diseases;
•6. Those who have participated in clinical trials of other drugs within 3 months;
•7. Those with severe impairment of heart, liver, and kidney functions (heart function grades 3 to 4, ALT and/or AST exceeding 1.5 times the upper limit of normal, and Cr exceeding the upper limit of normal);
•8. Those deemed unsuitable for inclusion by the investigator Other situations.

发起方

Huashan Hospital Affiliated to Fudan University